H.R. 124 · 118th Congress
Byron Nash Renal Medullary Carcinoma Awareness Act of 2023
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
GreenSponsor3 cosponsors · 2 D, 1 R
0 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill allows states to receive federal payment under Medicaid for 50% of their costs for providing education on the risk of renal medullary carcinoma to individuals with sickle cell disease. (Renal medullary carcinoma is a rare kidney disease usually found in individuals with the sickle cell trait.)
What it does: CRS summary · Introduced in House · Jan 9, 2023
Byron Nash Renal Medullary Carcinoma Awareness Act of 2023
This bill allows states to receive federal payment under Medicaid for 50% of their costs for providing education on the risk of renal medullary carcinoma to individuals with sickle cell disease. (Renal medullary carcinoma is a rare kidney disease usually found in individuals with the sickle cell trait.)
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Byron Nash Renal Medullary Carcinoma Awareness Act of 2023
Latest action (Jan 20, 2023): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jan 9, 2023
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.